Table 2.
Base case for cost per QALYs gained
| Gemcitabine plus cisplatin | Gemcitabine only | Incremental | |
|---|---|---|---|
| Cost (yen) | 15,446,575 | 12,328,228 | 3,118,347 |
| Eff. (QALMs) | 10.04 | 7.61 | 2.73 |
Incremental cost-effectiveness ratio (ICER) = 3 yen, 118,347/2.73 QALMs = 13,707,020 yen/QALY gained >6,000,000/QALYs gained (not cost-effective)
QALY (M) quality-adjusted life year (month)